MedPath

Triamcinolone

Generic Name
Triamcinolone
Brand Names
Allernaze, Aristocort, Aristocort R, Juulissa Pharmapak, Kenalog, Kourzeq, Marcaine, Nasacort, Oracort, Oralone, Pediaderm Ta, Triaderm, Trianex, Triderm, Triesence, Triloan Suik, Tritocin, Viaderm Kc, Xipere, Zilretta
Drug Type
Small Molecule
Chemical Formula
C21H27FO6
CAS Number
124-94-7
Unique Ingredient Identifier
1ZK20VI6TY
Background

Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.

Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis.

Indication

肾上腺皮质激素类药。主要用于过敏性与自身免疫性炎症性疾病。由于本品潴钠作用较弱，故一般不用作肾上腺皮质功能减退的替代治疗。

Associated Conditions
Acne, Acne Vulgaris, Acute Gouty Arthritis, Allergic Contact Dermatitis, Allergic Rhinitis (AR), Allergic Skin Reaction, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aphthous Stomatitis, Asthma, Atopic Dermatitis, Autoimmune Hemolytic Anemia, Berylliosis, Bullous dermatitis herpetiformis, Chronic Eczema, Chronic Inflammatory Skin Diseases, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Crohn's Disease (CD), Dental Cavity, Dermatitis, Dermatomyositis (DM), Diaper Rash, Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Erythroderma, Fungal Infections, Fungal infectious disorders of the Beard, Fungal skin infection, Gingivitis, Haemorrhoids, Hemangiomas, Hypercalcemia, Inflammation of Mouth, Intertrigo, Itching of the Anus, Itching of the External Genitalia, Itching of the Foot, Itching of the genitals, Itching of the hand, Juvenile Idiopathic Arthritis (JIA), Keloids Scars, Leukemias, Lichen Planus (LP), Lichen simplex chronicus, Lymphoma, Macular Edema, Mycosis Fungoides (MF), Mycotic Eczema, Necrobiosis lipoidica diabeticorum, Neurodermatitis, Nummular Dermatitis, Ocular Inflammation, Ophthalmia, Sympathetic, Oral Erosive Lichen Planus, Otitis Externa, Pemphigus, Pericarditis, Polymyositis, Postherpetic Neuralgia, Primary adrenocortical insufficiency, Proteinuria, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Purulent Wounds, Pyoderma caused by susceptible bacteria, Regional Enteritis, Rheumatoid Arthritis, Ringworm Folliculitis, Seborrheic Dermatitis, Seborrheic Dermatitis, Eczematous, Secondary Impetiginization, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Skin chapped, Stomatitis, Denture, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Tinea Corporis, Transfusion Reactions, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Urticaria, Uveitis, Wound Infections, Acute Bursitis, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Corticosteroid-responsive dermatoses, Cutaneous candidiasis, Cystic tumour of the ganglia, Exfoliative erythroderma, Granuloma annulare lesions, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Oral infections, Oral lesions, Severe Erythema multiforme, Subacute Dermatitis, Eczematous, Symptomatic Sarcoidosis, Ulceration of the mouth, Ulcerative stomatitis
Clinical Trials
Related News

Pacira BioSciences Settles EXPAREL Patent Litigation with Fresenius Kabi, Securing Market Exclusivity Until 2030

• Pacira BioSciences has reached a settlement with Fresenius Kabi and other companies regarding patent litigation for its non-opioid pain therapy EXPAREL, allowing limited generic entry beginning in early 2030. • The agreement permits Fresenius to sell volume-limited amounts of generic bupivacaine liposome injectable suspension starting with high-single-digit percentages, gradually increasing to a maximum in the high thirties by the final years. • Unlimited generic production by Fresenius will not be permitted until 2039, significantly before EXPAREL's last patent expiration in 2044, allowing Pacira to maintain market dominance for its flagship product.

Pacira BioSciences Advances Novel Gene Therapy for Knee Osteoarthritis with First Patient Dosed in Phase 2 Trial

• Pacira BioSciences has dosed the first patient in its Phase 2 ASCEND study evaluating PCRX-201, a locally administered gene therapy designed to treat osteoarthritis of the knee by boosting anti-inflammatory protein production. • The innovative therapy utilizes Pacira's proprietary high-capacity adenovirus vector platform and features an inducible promoter that activates IL-1Ra expression during inflammation and deactivates when inflammation subsides. • In previous Phase 1 trials, PCRX-201 demonstrated sustained pain relief for at least two years across all osteoarthritis severity levels, with topline results from the current two-part study expected by late 2026.

Harrow Secures Five-Year Supply Agreement for TRIESENCE® and Initiates Development of Next-Generation Version

• Harrow has executed a five-year strategic supply and development agreement with the current contract manufacturing organization for TRIESENCE®, ensuring stable supply of the ocular corticosteroid. • The company has begun developing an enhanced version of TRIESENCE®, with plans to submit a new drug application (NDA) to the FDA by the end of 2027. • TRIESENCE® is FDA-approved for visualization during vitrectomy and treatment of ocular inflammatory conditions unresponsive to topical corticosteroids, addressing a product previously on the FDA's Drug Shortage List.

Clearside's CLS-AX Phase 2b Trial Data Shows Promise in Treatment-Naïve AMD Patients

• New subgroup analyses from Clearside Biomedical's ODYSSEY Phase 2b trial provide strategic insights for upcoming Phase 3 program in neovascular age-related macular degeneration. • Data presented at the Angiogenesis 2025 meeting supports focusing on treatment-naïve patients and implementing specific visual acuity criteria for future trials. • The 36-week ODYSSEY trial employed a robust design, being randomized, double-masked, and active-controlled across multiple centers.

China's NMPA Accepts NDA for ARCATUS for Uveitic Macular Edema

• Arctic Vision's New Drug Application (NDA) for ARCATUS has been accepted for review by China's National Medical Products Administration (NMPA). • ARCATUS, known as XIPERE in the U.S., is a suprachoroidal therapy for uveitic macular edema (UME) utilizing Clearside's SCS Microinjector. • The NDA is supported by positive Phase 3 clinical trial results in China, demonstrating significant visual acuity improvement and edema control. • ARCATUS has already been approved in the U.S., Australia, and Singapore, marking continued global expansion of Clearside's SCS injection platform.

Global Diabetic Retinopathy Clinical Trials Landscape Analysis Reveals Key Research Trends for 2024

• A comprehensive analysis of global diabetic retinopathy clinical trials has been released, offering insights into trial distribution across G7 and E7 countries and various research phases. • The report highlights significant trends in trial enrollment patterns over the past five years, providing valuable data for healthcare stakeholders and pharmaceutical companies. • The analysis covers detailed assessment of trial statuses, sponsor types, and endpoint evaluations, helping identify key opportunities and challenges in diabetic retinopathy research.

Pacira Receives FDA Clearance for Iovera System to Treat Chronic Back Pain

• Pacira BioSciences has received FDA clearance for its Iovera system with a longer-needle Smart Tip to treat chronic low back pain, offering a drug-free alternative. • The Iovera system uses cryoneurolysis to temporarily halt nerve signals, providing pain relief that can last for months, and has shown benefits in a pilot study. • This approval expands the use of the Iovera system, already used for knee, hip, shoulder, and ankle pain, to address the significant health issue of chronic low back pain. • Pacira's focus on non-opioid pain therapies is further strengthened by this clearance, complementing their existing products like EXPAREL and ZILRETTA.

FDA Moves to Remove Oral Phenylephrine as Decongestant Due to Ineffectiveness

• The FDA is moving to phase out oral phenylephrine, a common decongestant in over-the-counter cold medicines, after determining it is no more effective than a placebo. • This decision follows expert reviews of studies dating back to the 1960s, which revealed flaws and questionable data regarding phenylephrine's efficacy in oral form. • Consumers may need to switch to alternatives like pseudoephedrine (available behind the counter) or nasal sprays for congestion relief. • The FDA's decision is expected to take several months to finalize, allowing time for public comment and for drug manufacturers to reformulate or remove affected products.

Clearside Biomedical Highlights Suprachoroidal Delivery Tech at Global Medical Meetings

• Clearside Biomedical showcased its suprachoroidal delivery technology and pipeline programs at medical meetings across Asia, Europe, and the United States. • The company's SCS Microinjector has been used in over 10,000 injections, establishing Clearside as a leader in suprachoroidal space drug delivery. • Presentations included ODYSSEY topline results, XIPERE real-world data, and posters on their suprachoroidal delivery platform at APVRS Congress. • Clearside's CLS-AX program for wet AMD is Phase 3 ready, with additional Phase 2b ODYSSEY trial data to be presented at upcoming meetings.

Clearside Biomedical Highlights Suprachoroidal Delivery Technology at Global Medical Meetings

• Clearside Biomedical presented its suprachoroidal delivery technology and pipeline program data at medical meetings across Asia, Europe, and the United States. • ODYSSEY trial topline results for CLS-AX in wet AMD were presented at the Ophthalmology Innovation Summit and the Asia-Pacific Vitreo-Retina Society (APVRS) Congress. • Clearside hosted suprachoroidal injection procedure demonstrations at APVRS, showcasing the SCS Microinjector® technology and novel delivery approach. • Arctic Vision is advancing XIPERE towards potential approval in China, Australia, and Singapore, increasing interest in Clearside's delivery approach.

Clearside Biomedical's CLS-AX Shows Promise in Wet AMD Phase IIb Trial

• Clearside Biomedical's CLS-AX met primary and secondary endpoints in a Phase IIb trial for wet AMD, demonstrating stable visual acuity and central subfield thickness. • The ODYSSEY trial highlighted an 84% reduction in injection frequency with CLS-AX, with 67% of patients needing no additional injections for six months. • CLS-AX, administered via the SCS Microinjector, showed a positive safety profile with no serious ocular or treatment-related adverse events. • The trial results support advancing CLS-AX into Phase III development as a potential long-acting treatment for wet AMD.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy